LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "nab" as a keyword



Levels of Natural Antibodies Before and After Immunoglobulin Replacement Treatment Affect the Clinical Phenotype in Common Variable Immunodeficiency

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Immunology"

DOI: 10.1007/s10875-024-01805-7

Abstract: Natural antibodies (NAbs) occurring in individuals without prior exposure to specific antigens, provide direct first barrier protection against pathogens, and exert immunoregulation thus actively contributing to the maintenance of immune homeostasis, controlling inflammatory processes and… read more here.

Keywords: treatment; igm nab; natural antibodies; nab ... See more keywords

Health care costs and treatment patterns among metastatic pancreatic cancer (MPC) patients (pts) initiating first-line (1L) on nab-paclitaxel/gemcitabine (nab-P+G) or FOLFIRINOX (FFX).

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.4_suppl.415

Abstract: 415Background: The economic burden of MPC is substantial while treatment options are limited. This study aimed to compare healthcare costs and treatment patterns in MPC patients who initiated nab-P+G or FFX in a large insured… read more here.

Keywords: treatment; nab; mpc patients; health ... See more keywords

Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.4_suppl.91

Abstract: 91Background: Nab-paclitaxel (nab-PTX) is a candidate as second-line chemotherapy for gastric cancer, with the response rate (RR) of 28% and overall survival (OS) of 9.2 months in that setting in Japan (J-0200). Adverse events (AE)… read more here.

Keywords: reduction; reduction criteria; nab; line chemotherapy ... See more keywords

Total healthcare, treatment, and supportive care costs among metastatic pancreatic cancer (MPC) patients (pts) treated with either nab-paclitaxel/gemcitabine (nab-P+G) or FOLFIRINOX (FFX) in the first-line (1L) setting.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.8_suppl.20

Abstract: 20Background: The economic burden of MPC is substantial while treatment options are limited. This study compared treatment, supportive care, and total health care costs in MPC pts who initiated nab-P+G or FFX in a large… read more here.

Keywords: care costs; supportive care; treatment; nab ... See more keywords

Patient and Clinical Factors at Admission Affect the Levels of Neutralizing Antibodies Six Months after Recovering from COVID-19

Sign Up to like & get
recommendations! Published in 2022 at "Viruses"

DOI: 10.3390/v14010080

Abstract: The rate of decline in the levels of neutralizing antibodies (NAbs) greatly varies among patients who recover from Coronavirus disease 2019 (COVID-19). However, little is known about factors associated with this phenomenon. The objective of… read more here.

Keywords: nab; neutralizing antibodies; six months; covid ... See more keywords